Introduction
Cutaneous T cell lymphoma (CTCL) encompasses a spectrum of clinical presentations unified by the immunologic features of the neoplastic T cells. CTCL is a clonal malignancy 1 of CD4 +2 , helper T cells 3, 4 expressing a memory phenotype 5 and propensity to accumulate in the epidermis in close proximity to Langerhans cells 6 (LC), an immature member of the DC series 7 .
Epidermal association of CTCL cells with LC is so distinctive that it is considered a diagnostic hallmark of the malignancy labeled "Pautrier micro-abscesses" 6 . Proliferation of CTCL cells in the epidermis in association with LC has suggested that the tumor cells' growth is stimulated by LC-mediated antigen presentation and led to the hypothesis that CTCL is a disease of chronic antigen stimulation whose growth is promoted by LC presentation of viral, bacterial or chemically modified peptides 8, 9 .
Despite the presence in CTCL patients of circulating populations of CD8 T cells 10 that recognize class I MHC displayed tumor-specific peptides derived from the malignant T cell's clonotypic T cell receptor 11, 12 , the disease persists and disseminates, indicating that the malignancy commonly evades immunosurveillance. We developed a culture system that allowed assessment of the factors that promote the growth of CTCL cells 13 and clarified their interaction with immature DC.
In the cultures, proliferation of both CTCL cells and autologous myeloid DC, requires direct membrane contact between the two cell populations, suggesting a dynamic "cross-talk" between them. Only immature autologous DC support CTCL cell replication and CTCL cell production of IL-10 maintains long-term DC immaturity 13 . After 3 months of culture, the DC finally progresses to maturity, revealed by increased expression of surface class II and only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013 . bloodjournal.hematologylibrary.org From cytoplasmic DC-lamp 7 . DC maturation abruptly truncates the synergy between the DC and CTCL cells leading to degranulation and death of the DC, followed shortly thereafter by the death of the CTCL cells.
In the current studies, we determined that after exposure to immature DC loaded with apoptotic CTCL cells, the TCR of the malignant T cell is engaged and the CTCL cells respond by proliferating, up-regulating cytoplasmic cytotoxic T lymphocyte antigen-4 (CTLA-4), FoxP3, membrane CD25 and secreting the immunosuppressive cytokines, IL-10 and TGF-, all features of T-regulatory (Treg) cells 14 . Interference with access to DC class II molecules diminishes the capacity of the tumor-loaded DC to trigger CTLA-4 up-regulation in CTCL cells.
Treg cells comprise 5-10% of the peripheral blood pool and are so named, because they regulate the activities of T cell subsets responding to self antigens 15 , infectious agents 16 , and transplantation antigens 17 . Treg cells directly suppress T cell activation, possibly through membrane expression of molecules such as CTLA-4 18 , and may mediate distal antigen-nonspecific suppression, through secretion of cytokines such as IL-10 and TGF-1 19, 20 .
Our studies demonstrate that when CTCL cells adopt a Treg phenotype they function as only.
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Materials and Methods
Cell Culture: Cultures of CTCL cells and myeloid DC were established as described 13 .
Peripheral leukocytes were isolated from a leukapheresis harvest from CTCL patients, (informed consent was provided according to the declaration of Helsinki and following Yale Human
Investigational Review Board guidelines) and cultured with GM-CSF (800 U/ml), IL-4 (1000 U/ml), IL-2 (10 U/ML) and IL-7 (10 ng/ml, R&D Systems, Minneapolis, MN) in RPMI 1640/10% AB serum, 5% FCS (GIBCO, Gaithersburg, MD). On initial isolation, the majority of the T cells were CTLA-4 negative. Episodic identification of CTLA-4 + CTCL cells was related to high numbers of apoptotic cells in cultures and CTLA-4 expression reverted to background when CTCL cells were re-cultured overnight in the absence of apoptotic cells (Supplemental Fig   1) . Induction of Treg CTCL cells was replicated in more than 10 cultures and neither the source of the CTCL cells or culture length impacted up-regulation of a Treg phenotype.
Cell Purification: CTCL cells were purified away from DC by incubation with CD4 antibody conjugated to magnetic beads (Miltenyi Biotech, Auburn CA) and passage over a column in a magnetic field, following the manufacturer's instructions. Immature DC were weakly CD4 positive and did not co-purify. CD4 magnetic bead separation resulted in 98% + 0.5 CD4 + T cell purity and 91% + 2 DC enrichment in the column effluent.
Immunophenotyping: Monoclonal antibodies were either directly conjugated to fluorescein (FITC) or phycoerythrin (PE) or stained with a secondary antibody (goat anti-murine Ig). Membrane and cytoplasmic antigen co-expression was examined by a fixation and permeabilization kit (Coulter-Immunotech), using antibodies conjugated to FITC or PE.
Background staining was determined with isotype controls conjugated to FITC or PE.
Apoptosis and DC loading:
Purified CTCL cells (1-6x10 6 /ml,100 µl/well) were rendered apoptotic by CD3 antibody (3.5 µg/0.5 ml purified CD3, 30 min, 23 0 C, Coulter). Apoptosis was monitored by annexin-FITC staining. CD4 antibody of the same isotype and concentration that binds to the CTCL cells but does not cause apoptosis was used as a negative control. Unbound antibody was removed by extensive washing.
A CD3 dose response curve revealed maximal apoptosis of CTCL cells was achieved at a CD3 dose of 33 µg/ml and 1 hour incubation (Supplemental Fig 2a) . All concentrations of CD3 tested mediated sufficient apoptosis for Treg cell induction. In addition, no concentration of CD3 alone in the absence of DC, caused induction of a Treg phenotype (Supplemental Fig 2b) .
In general, apoptotic tumor cells (1x10 6 cells) were added to purified DC (1x10 5 ) and cocultivated overnight to permit engulfment of the apoptotic tumor. Control CD4 T cells were rendered apoptotic by treatment with CD3 (3.5 µg/0.5 ml) and -irradiation (3000 rads, Cesium source) and added to purified DC. In some experiments allogeneic CTCL cells were rendered apoptotic by CD3 binding and used to load DC autologous to responding CTCL cells. Proliferative response to tumor-loaded DC: When CTCL cells were purified and cultured alone with supportive cytokines, they did not proliferate (Fig 3a) . Purified CTCL cells co- Therefore, access to newly synthesized class II molecules is required for CTLA-4 expression and induction of a Treg phenotype in CTCL.
Apoptotic material from both malignant and normal T cells stimulates a Treg phenotype:
In figure 7 , CTCL cells and DC were isolated from cultures established from 2 different CTCL patients. Baseline CTLA-4 expression was found in co-cultures of freshly purified CTCL cells only.
For (Fig 7a & e) . Co-cultivation of CTCL cells with DC that had been loaded with autologous apoptotic tumor cells resulted in upregulation of cytoplasmic CTLA-4 (Fig 7b & c) and loss of expression of cell membrane CD3 (Fig 7b) . Pulsing viable autologous CTCL cells onto autologous DC did not induce CTLA-4 expression in CTCL cells (Fig 7d) . When allogeneic CTCL cells were rendered apoptotic and used to pulse DC autologous to the responding CTCL cells, CTLA-4 expression was upregulated (Fig 7f & h) and loss of membrane TCR expression was found (Fig 7h) . Viable allogeneic CTCL cells pulsed onto DC, autologous to the responding CTCL cells, did not trigger CTLA-4 expression (Fig 7g) . Therefore, when either autologous or allogeneic apoptotic CTCL cells are used as a source of apoptotic material to pulse DC autologous to the responding CTCL cells, a Treg phenotype could be induced.
In addition, when normal control CD4 T cells were stimulated by CD3-treatment and rendered apoptotic with -irradiation, they also served as a source of apoptotic material that could induce a Treg phenotype in responding CTCL cells. CTCL cells stimulated with non-loaded DC expressed baseline levels of CTLA-4 (Fig 7i) , but when the CTCL cells responded to DC fed apoptotic autologous tumor they up-regulated CTLA-4 expression (43% CTLA-4 + , Fig 7j) .
When normal control CD4 T cells were first activated with CD3, and then rendered apoptotic by -irradiation and fed to the DC isolated from the CTCL patient they were approximately half as efficient as autologous apoptotic CTCL cells in stimulating up-regulation of CTLA-4 expression (23% CTLA-4+, Fig 7k) . Therefore, the source of apoptotic material that drives a Treg phenotype in CTCL is not restricted to tumor cells and can be derived from normal CD4 T cells. Other studies demonstrate that CTLA-4 is induced after TCR engagement in the cytoplasm of Treg cells and that CTLA-4 is rapidly translocated to the membrane site of the TCR-MHCpeptide tri-molecular complex 28 where it binds with a higher affinity to the B7 co-stimulatory For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From
